National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 4) (Cth)

PB 41 of 2021

National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 4)

I, THEA CONNOLLY, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, and delegate of the Minister for Health and Aged Care, make the following determination.

Dated    28 April          2021

THEA CONNOLLY  

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

Contents

1...... Name

2...... Commencement............................................................................................................................... 1

3...... Authority......................................................................................................................................... 1

4 ..... Schedule.......................................................................................................................................... 1

Schedule 1—Amendments   2

National Health (Continued Dispensing - Emergency Measures) Determination 2020         2

1  Name

(1) This instrument is the National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 4).

(2) This instrument may also be cited as PB 41 of 2021.

2  Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1.  The whole of this instrument	1 May 2021.

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

This instrument is made under subsection 89A(3) of the National Health Act 1953.

4  Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Continued Dispensing – Emergency Measures) Determination 2020

1. Schedule 1, entry for Aciclovir

(a)insert as first entry:

Eye ointment 30 mg per g, 4.5 g Application to the eye

(b)omit:

Eye ointment 30 mg per g, 4.5 g (Acivision) Application to the eye

1. Schedule 1, after entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg

insert:

Cannabidiol Oral liquid 100 mg per mL, 100 mL Oral

1. Schedule 1, entry for Mesalazine

substitute:

Mesalazine	Enemas 1 g in 100 mL, 7	Rectal
Enemas 2 g in 60 mL, 7	Rectal
Enemas 4 g in 60 mL, 7	Rectal
Rectal foam 1 g per applicatorful, 14 applications, aerosol 80 g	Rectal
Sachet containing granules, 500 mg per sachet	Oral
Sachet containing granules, 1 g per sachet	Oral
Sachet containing granules, 1.5 g per sachet	Oral
Sachet containing granules, 3 g per sachet	Oral
Sachet containing prolonged release granules, 1 g per sachet	Oral
Sachet containing prolonged release granules, 2 g per sachet	Oral
Sachet containing prolonged release granules, 4 g per sachet	Oral
Suppository 1 g	Rectal
Suppository (moulded) 1 g	Rectal
Tablet 250 mg (enteric coated)	Oral
Tablet 500 mg (enteric coated)	Oral
Tablet 500 mg (prolonged release)	Oral
Tablet 800 mg (enteric coated)	Oral
Tablet 1 g (enteric coated)	Oral
Tablet 1 g (prolonged release)	Oral
Tablet 1.2 g (prolonged release)	Oral
Tablet 1.6 g (enteric coated)	Oral

1. Schedule 1, entry for Norethisterone with ethinylestradiol

omit:

Pack containing 21 tablets 1 mg‑35 micrograms and 7 inert tablets USP Oral